• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

350例T1/T2、N0/N1期乳腺癌中的蛋白酪氨酸激酶活性。初步结果。

Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.

作者信息

Bolla M, Rostaing-Puissant B, Bottari S P, Chedin M, Marron-Charriere J, Colonna M, Berland E, Chambaz E

机构信息

Biochemistry Department, CHU A. Michallon, Grenoble, France.

出版信息

Breast Cancer Res Treat. 1996;39(3):327-34. doi: 10.1007/BF01806161.

DOI:10.1007/BF01806161
PMID:8877013
Abstract

Protein tyrosine kinases (PTKs) are a family of enzymes sharing a highly conserved catalytic domain which phosphorylates substrate proteins on tyrosine residues. PTKs play a major role in the transduction of the mitogenic signal and are involved in the control of cell proliferation, differentiation, and transformation processes. PTKs can be subdivided into two major types: membrane associated PTKs consisting essentially of growth factor receptors (receptor tyrosine kinases or RTKs) and cytosolic PTKs involved in the intracellular transduction of mitogenic and differentiation signals. From January 1988 to January 1992, PTK activity was assayed in cytosolic fractions prepared from 350 T1-T2, N0-N1 M0, breast carcinomas. Enzymatic activity was measured using phosphate transfer from [32P]-ATP to poly-Glu-Tyr as an artificial substrate. According to our previously reported pilot study, we chose a cut-off value of 12 pmol 32P incorporated min-1 mg-1 protein, corresponding to the median value. We found positive PTK levels (> or = 12 pmol/min/mg) to be correlated with a loss of differentiation according to Scarff-Bloom grade (p < 0.001), negative PR (p = 0.03) and ER status (p = 0.04). With a median follow-up of 30 months (0-82), patients with a positive PTK level presented a smaller 3-year disease free survival than in the PTK negative group of patients (p = 0.07). In Cox multivariate analysis including pT, pN, Scarff-Bloom grade, PR and ER, PTK activity does not emerge as a significant prognostic factor.

摘要

蛋白酪氨酸激酶(PTK)是一类酶,它们共享一个高度保守的催化结构域,该结构域可使底物蛋白的酪氨酸残基磷酸化。PTK在有丝分裂原信号转导中起主要作用,并参与细胞增殖、分化和转化过程的控制。PTK可分为两大类:主要由生长因子受体组成的膜相关PTK(受体酪氨酸激酶或RTK)和参与有丝分裂原及分化信号细胞内转导的胞质PTK。1988年1月至1992年1月,对350例T1-T2、N0-N1、M0期乳腺癌的胞质组分进行了PTK活性检测。酶活性通过将[32P]-ATP的磷酸基团转移至聚谷氨酸-酪氨酸作为人工底物来测定。根据我们之前报道的初步研究,我们选择了12 pmol 32P掺入量min-1 mg-1蛋白的临界值,该值对应于中位数。我们发现,根据斯卡夫-布鲁姆分级(p < 0.001)、孕激素受体(PR)阴性(p = 0.03)和雌激素受体(ER)状态(p = 0.04),PTK水平阳性(≥12 pmol/min/mg)与分化丧失相关。中位随访30个月(0-82个月),PTK水平阳性的患者3年无病生存率低于PTK阴性组患者(p = 0.07)。在包括pT、pN、斯卡夫-布鲁姆分级、PR和ER的Cox多变量分析中,PTK活性未成为显著的预后因素。

相似文献

1
Protein tyrosine kinase activity in 350 T1/T2, N0/N1 breast cancer. Preliminary results.350例T1/T2、N0/N1期乳腺癌中的蛋白酪氨酸激酶活性。初步结果。
Breast Cancer Res Treat. 1996;39(3):327-34. doi: 10.1007/BF01806161.
2
Prognostic assessment of PTK activity in T1-T2, N0-N1, M0 breast cancer: a multicentric retrospective study.T1-T2期、N0-N1期、M0期乳腺癌中PTK活性的预后评估:一项多中心回顾性研究
Breast Cancer Res Treat. 2002 Jul;74(2):135-41. doi: 10.1023/a:1016157901500.
3
Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.蛋白质酪氨酸激酶活性作为乳腺癌预后参数的初步研究
Breast Cancer Res Treat. 1993;26(3):283-7. doi: 10.1007/BF00665806.
4
Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product.
Cancer Res. 1992 Sep 1;52(17):4773-8.
5
Protein tyrosine kinase activity in breast cancer and its relation to prognostic indicators.乳腺癌中的蛋白酪氨酸激酶活性及其与预后指标的关系。
Anticancer Res. 1996 Sep-Oct;16(5B):3037-41.
6
Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.249例淋巴结阳性乳腺癌患者胞质酪氨酸激酶活性的预后价值
Br J Cancer. 1994 Aug;70(2):304-8. doi: 10.1038/bjc.1994.297.
7
Prognostic value of quantitative cytometry in a series of 415 T1T2/N0N1/M0 breast cancer patients--preliminary results.415例T1T2/N0N1/M0期乳腺癌患者定量细胞计数的预后价值——初步结果
Eur J Cancer. 1996 Sep;32A(10):1680-5. doi: 10.1016/0959-8049(96)00174-8.
8
Identification of cytosolic protein tyrosine kinases of human prostate by renaturation after SDS/PAGE.通过SDS/聚丙烯酰胺凝胶电泳后复性鉴定人前列腺的胞质蛋白酪氨酸激酶
Biochem J. 1992 Jun 15;284 ( Pt 3)(Pt 3):653-8. doi: 10.1042/bj2840653.
9
Protein tyrosine kinase activity assays.蛋白质酪氨酸激酶活性测定。
Curr Protoc Pharmacol. 2001 May;Chapter 3:Unit3.5. doi: 10.1002/0471141755.ph0305s05.
10
Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters.
Breast Cancer Res Treat. 1994;29(3):265-70. doi: 10.1007/BF00666480.

引用本文的文献

1
Structure-activity relationship of halophenols as a new class of protein tyrosine kinase inhibitors.作为一类新型蛋白质酪氨酸激酶抑制剂的卤代酚的构效关系
Int J Mol Sci. 2011;12(9):6104-15. doi: 10.3390/ijms12096104. Epub 2011 Sep 19.

本文引用的文献

1
Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。
J Biol Chem. 1951 Nov;193(1):265-75.
2
JAK protein tyrosine kinases: their role in cytokine signalling.JAK蛋白酪氨酸激酶:它们在细胞因子信号传导中的作用。
Trends Cell Biol. 1994 Jun;4(6):207-12. doi: 10.1016/0962-8924(94)90143-0.
3
CD45 specifically modulates binding of Lck to a phosphopeptide encompassing the negative regulatory tyrosine of Lck.CD45 特异性调节 Lck 与包含 Lck 负调节酪氨酸的磷酸肽的结合。
EMBO J. 1993 Jan;12(1):315-21. doi: 10.1002/j.1460-2075.1993.tb05659.x.
4
Reversible tyrosine phosphorylation and cell cycle control.可逆性酪氨酸磷酸化与细胞周期调控。
Semin Cell Biol. 1993 Dec;4(6):433-42. doi: 10.1006/scel.1993.1051.
5
Protein tyrosine kinase activity as a prognostic parameter in breast cancer, a pilot study.蛋白质酪氨酸激酶活性作为乳腺癌预后参数的初步研究
Breast Cancer Res Treat. 1993;26(3):283-7. doi: 10.1007/BF00665806.
6
Signal transduction. Cytokine connections.信号转导。细胞因子连接。
Nature. 1993 Nov 11;366(6451):114-6. doi: 10.1038/366114a0.
7
Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.249例淋巴结阳性乳腺癌患者胞质酪氨酸激酶活性的预后价值
Br J Cancer. 1994 Aug;70(2):304-8. doi: 10.1038/bjc.1994.297.
8
Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters.
Breast Cancer Res Treat. 1994;29(3):265-70. doi: 10.1007/BF00666480.
9
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours.编码一种在人类乳腺肿瘤中表达的新型非受体酪氨酸激酶brk的cDNA的克隆与鉴定
Oncogene. 1994 Aug;9(8):2383-90.
10
Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.neu/p185与表皮生长因子受体酪氨酸激酶的相互作用:对细胞转化和肿瘤治疗的意义。
J Cell Biochem. 1993 Sep;53(1):61-73. doi: 10.1002/jcb.240530108.